
1
Total Mentions
1
Documents
0
Connected Entities
HOUSE_OVERSIGHT_024003 - HOUSE_OVERSIGHT_024116
re partnerships that have generated non-dilutive capital for the company. Examples of three novel product platform companies in the NLV portfolio are Pearl Therapeutics (NLV-I, private, pulmonology, exited at 2.5x plus milestones), Epizyme (NLV-II, NASDAQ: EPZM, oncology, exited at 2.0x), and Principia (NLV-IL privat
Page: HOUSE_OVERSIGHT_024044 →No connected entities